Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
University of Miami · University of Pisa · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
688
total citations
- FWCI
- 41.53
- Percentile
- 100%
- References
- 54
Citations per year
Authors
17- RLRiccardo LencioniCorresponding
University of Miami, University of Pisa
- JMJosep M. Llovet
Institució Catalana de Recerca i Estudis Avançats, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Icahn School of Medicine at Mount Sinai
- GHGuohong Han
Air Force Medical University, Xijing Hospital
- WYWon Young Tak
Kyungpook National University Hospital
- JYJiamei Yang
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
Topics & keywords
Topics
Keywords
- Sorafenib
- Medicine
- Placebo
- Clinical endpoint
- Hepatocellular carcinoma
- Hazard ratio
- Internal medicine
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.